Are AbbVie and Allergan Really Better Together?

The news that AbbVie (NYSE: ABBV) had inked a $63 billion deal to buy Allergan (NYSE: AGN) was not met with applause on Wall Street Tuesday. Given that the share price of Allergan is now trading far below the bid price, there are clearly questions about whether the acquisition will go through. And the response reflected in AbbVie's stock move makes it clear that investors think it's overpaying -- though the deal price is less than half of what Pfizer intended to pay just three years ago.